News

Filter

Current filters:

Rocheonartuzumab

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

Roche advised to stop Ph III onartuzumab METLung study on lack of efficacy

03-03-2014

An independent data monitoring committee has recommended that Swiss drug major Roche’s Phase III METLung…

BiotechnologyGenentechonartuzumabOncologyResearchRoche

COMPANY SPOTLIGHT

Menarini

Back to top